<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6069">
  <stage>Registered</stage>
  <submitdate>5/09/2016</submitdate>
  <approvaldate>5/09/2016</approvaldate>
  <nctid>NCT02894736</nctid>
  <trial_identification>
    <studytitle>Home-Administered Trial of Direct Current Stimulation</studytitle>
    <scientifictitle>Home-administered Transcranial Direct Current Stimulation (tDCS) Treatment for Depression</scientifictitle>
    <utrn />
    <trialacronym>HAT-DCS</trialacronym>
    <secondaryid>HC15010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Soterix tDCS machine

Experimental: Active tDCS - Soterix tDCS machine is used to administer active stimulation


Treatment: devices: Soterix tDCS machine
Soterix tDCS machine - miniCT supervised neuromodulation system

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Montgomery Asberg Depression Rating Scale for Depression (MADRS)</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject meets criteria for a DSM-IV Major Depressive Episode, lasting more than 4
             weeks

          -  Total MADRS score = 20</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis of any DSM-IV psychotic disorder

          -  History of drug or alcohol abuse or dependence in the preceding 3 months

          -  High suicide risk

          -  Clinically defined neurological disorder or insult

          -  Metal in the cranium or skull defects

          -  Skin lesions on the scalp (e.g. cuts, abrasions, rashes) at the proposed electrode
             sites

          -  Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Black Dog Institute - Randwick, Sydney</hospital>
    <postcode>2031 - Randwick, Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Transcranial Direct Current Stimulation (tDCS) is a novel non-invasive brain stimulation
      treatment that is effective with no significant side effects. It can potentially be
      self-administered by patients in their own homes with remote monitoring, substantially
      reducing treatment costs and increasing accessibility, including to remote areas. This study
      will evaluate the feasibility and efficacy of home-administered tDCS treatment for
      depression.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02894736</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Angelo Alonzo, BSc(Hons)/BA, PhD</name>
      <address>University of New South Wales / Black Dog Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Angelo Alonzo, BSc(Hons)/BA, PhD</name>
      <address />
      <phone>+61-2-93822987</phone>
      <fax />
      <email>a.alonzo@unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>